Neuroblastoma UK welcomes advancement of potential new treatment
Fadraciclib has passed safety trials and shown early efficacy
Read More
Tag: The Institute of Cancer Research
‘Half’ the current chemo could prevent testicular cancer returning
Testicular cancer is the most common cancer affecting young men, with many patients being diagnosed in their twenties or thirties.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
